GlobeNewswire·Aug 14, 2026, 7:15 AM ET

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

OTLK OTLKW

Outlook Therapeutics reported a net loss of $20.3 million ($0.15 per share) for the third quarter of fiscal year 2026 ended June 30, 2026, compared to a $20.2 million loss in the prior year period.
The company announced an adjusted net loss of $10.9 million ($0.09 per share) for the quarter, excluding non-cash items such as changes in fair value of warrants and debt extinguishment costs.
LYTENAVA, the only FDA-approved ophthalmic bevacizumab for wet AMD, is advancing toward a U.S. commercial launch by the end of calendar 2026.
Management projects potential annual U.S. sales for LYTENAVA to exceed $500 million by 2030.
The company plans to submit an application for a permanent HCPCS code by October 1, 2026, to support reimbursement following the U.S. launch.
Outlook Therapeutics is expanding commercial capabilities in Europe, with active launches in Germany, Austria, & the UK, a planned Netherlands launch later in 2026, & an anticipated Swiss launch in 2027.
Subsequent to the quarter end in August 2026, the company completed a public offering of 55,555,556 shares & warrants, generating approximately $51.1 million in net proceeds.
As of June 30, 2026, the company held $11.2 million in cash & cash equivalents, excluding proceeds from the recent public offering.
The company will host a conference call on August 14, 2026, at 8:30 AM ET to discuss these third-quarter results & business updates.
LYTENAVA is indicated for the treatment of neovascular (wet) age-related macular degeneration, with common adverse reactions including conjunctival hemorrhage, eye pain, & vitreous floaters.